Retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancer
Introduction: Head and neck cancer (HNC) has large worldwide prevalence and accounts for almost 5% among all types of cancers. Nimotuzumab is a humanized anti-epidermal growth factor receptor monoclonal antibody that has shown promising results in patients with HNC. The present retrospective case st...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | Journal of Radiation and Cancer Research |
| Subjects: | |
| Online Access: | http://www.journalrcr.org/article.asp?issn=0973-0168;year=2017;volume=8;issue=2;spage=108;epage=111;aulast=Huilgol |
| _version_ | 1828492013337575424 |
|---|---|
| author | Nagraj Gururaj Huilgol Ajit Nair Sameer Chaudhari Dilip Pawar |
| author_facet | Nagraj Gururaj Huilgol Ajit Nair Sameer Chaudhari Dilip Pawar |
| author_sort | Nagraj Gururaj Huilgol |
| collection | DOAJ |
| description | Introduction: Head and neck cancer (HNC) has large worldwide prevalence and accounts for almost 5% among all types of cancers. Nimotuzumab is a humanized anti-epidermal growth factor receptor monoclonal antibody that has shown promising results in patients with HNC. The present retrospective case study aimed at investigating the response rate and adverse events (AEs) of a high dose of nimotuzumab in patients with HNC who are ineligible for platinum-based chemotherapy. Materials and Methods: Patients with locally advanced HNC who refused chemotherapy or were ineligible for platinum-based chemotherapy were analyzed in the study. Patients were given nimotuzumab along with radiotherapy (RT). The duration of each treatment cycle was 6 weeks. About 200 mg nimotuzumab was administered, twice weekly for 6 weeks. The patients who received at least one treatment cycle of targeted therapy and accompanied regular follow-ups were assessed for response rate measurements. Results: A total of six patients were enrolled in the study. A response rate of 100% was observed in the patients who completed the treatment. Complete and partial response was 60% and 40%, respectively, in HNC patients at the end of treatment. Three patients were reported with Grade II mucositis. No Grade III or IV AEs were observed in the patients. Conclusion: High dose of nimotuzumab along with RT enhanced response rate in patients with HNC who are ineligible for platinum-based chemotherapy without producing any additional toxicity. |
| first_indexed | 2024-12-11T11:13:00Z |
| format | Article |
| id | doaj.art-865e3770fde54355bcf5c64a7ee700ff |
| institution | Directory Open Access Journal |
| issn | 2588-9273 2468-9203 |
| language | English |
| last_indexed | 2024-12-11T11:13:00Z |
| publishDate | 2017-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Radiation and Cancer Research |
| spelling | doaj.art-865e3770fde54355bcf5c64a7ee700ff2022-12-22T01:09:26ZengWolters Kluwer Medknow PublicationsJournal of Radiation and Cancer Research2588-92732468-92032017-01-018210811110.4103/jrcr.jrcr_25_17Retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancerNagraj Gururaj HuilgolAjit NairSameer ChaudhariDilip PawarIntroduction: Head and neck cancer (HNC) has large worldwide prevalence and accounts for almost 5% among all types of cancers. Nimotuzumab is a humanized anti-epidermal growth factor receptor monoclonal antibody that has shown promising results in patients with HNC. The present retrospective case study aimed at investigating the response rate and adverse events (AEs) of a high dose of nimotuzumab in patients with HNC who are ineligible for platinum-based chemotherapy. Materials and Methods: Patients with locally advanced HNC who refused chemotherapy or were ineligible for platinum-based chemotherapy were analyzed in the study. Patients were given nimotuzumab along with radiotherapy (RT). The duration of each treatment cycle was 6 weeks. About 200 mg nimotuzumab was administered, twice weekly for 6 weeks. The patients who received at least one treatment cycle of targeted therapy and accompanied regular follow-ups were assessed for response rate measurements. Results: A total of six patients were enrolled in the study. A response rate of 100% was observed in the patients who completed the treatment. Complete and partial response was 60% and 40%, respectively, in HNC patients at the end of treatment. Three patients were reported with Grade II mucositis. No Grade III or IV AEs were observed in the patients. Conclusion: High dose of nimotuzumab along with RT enhanced response rate in patients with HNC who are ineligible for platinum-based chemotherapy without producing any additional toxicity.http://www.journalrcr.org/article.asp?issn=0973-0168;year=2017;volume=8;issue=2;spage=108;epage=111;aulast=HuilgolAnti-epidermal growth factor receptorepidermal growth factor receptorhead and neck cancernimotuzumab |
| spellingShingle | Nagraj Gururaj Huilgol Ajit Nair Sameer Chaudhari Dilip Pawar Retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancer Journal of Radiation and Cancer Research Anti-epidermal growth factor receptor epidermal growth factor receptor head and neck cancer nimotuzumab |
| title | Retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancer |
| title_full | Retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancer |
| title_fullStr | Retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancer |
| title_full_unstemmed | Retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancer |
| title_short | Retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancer |
| title_sort | retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancer |
| topic | Anti-epidermal growth factor receptor epidermal growth factor receptor head and neck cancer nimotuzumab |
| url | http://www.journalrcr.org/article.asp?issn=0973-0168;year=2017;volume=8;issue=2;spage=108;epage=111;aulast=Huilgol |
| work_keys_str_mv | AT nagrajgururajhuilgol retrospectiveanalysistoassessthefeasibilityofescalateddoseofnimotuzumabinpatientswithlocallyadvancedheadandneckcancer AT ajitnair retrospectiveanalysistoassessthefeasibilityofescalateddoseofnimotuzumabinpatientswithlocallyadvancedheadandneckcancer AT sameerchaudhari retrospectiveanalysistoassessthefeasibilityofescalateddoseofnimotuzumabinpatientswithlocallyadvancedheadandneckcancer AT dilippawar retrospectiveanalysistoassessthefeasibilityofescalateddoseofnimotuzumabinpatientswithlocallyadvancedheadandneckcancer |